Directory of Pharma Companies and News
Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofiâ€™s programs in oncology and immunology.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
|2019-03-14||Sanofi Genzyme Launches Innovative and Educational Audio Adventure Series for People Treated with ALPROLIXÂ®|
|2019-03-11||FDA approves DupixentÂ® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents|
|2019-03-08||FDA to undertake priority review of DupixentÂ® (dupilumab) for adults with inadequately controlled severe chronic rhinosi...|
|2019-03-01||New analyses to be presented at AAD for DupixentÂ® (dupilumab) and the burden of atopic dermatitis|
|2019-03-01||CHMP recommends approval of DupixentÂ® (dupilumab) for asthma indication|
|2019-02-25||Positive results presented from two Phase 3 trials of DupixentÂ® (dupilumab) in severe chronic rhinosinusitis with nasal ...|
|2019-02-07||Sanofi announces additional data on avalglucosidase alfa in Pompe disease|
|2019-02-06||FDA approves CabliviÂ® (caplacizumab-yhdp), the first NanobodyÂ®-based medicine, for adults with acquired thrombotic throm...|
|2019-02-05||Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refrac...|
|2019-01-30||Sanofi Presents Research Advances in Rare Genetic Diseases at 15th Annual WORLDSymposiumâ„˘ 2019|